title: Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study.
abstract: BACKGROUND
  Treatment of latent tuberculosis infection (LTBI) is an important aspect of tuberculosis control in the United States, but the effectiveness of this strategy is compromised by poor adherence to the recommended 9-month isoniazid regimen. In this study, we compared treatment completion and clinically recognized adverse drug reactions in patients prescribed 9 months of isoniazid therapy or 4 months of rifampin therapy for LTBI.
  
  
  METHODS
  Retrospective chart review of patients who received LTBI treatment at a public health clinic.
  
  
  RESULTS
  A total of 770 patients were prescribed 9 months of isoniazid therapy, and 1379 patients were prescribed 4 months of rifampin therapy. The percentages of patients who completed 80% or more of their prescribed treatment were 52.6% and 71.6% in the isoniazid and rifampin groups, respectively (P<.001). In multivariate logistic regression analysis, treatment regimen was independently associated with treatment completion (adjusted odds ratio for treatment completion, 2.88 for rifampin group vs isoniazid group; 95% confidence interval, 2.27-3.66). Clinically recognized adverse reactions resulting in permanent treatment discontinuation occurred in 4.6% and 1.9% of patients in the isoniazid and rifampin groups, respectively (P<.001). Clinically recognized hepatotoxicity was more common in the isoniazid group (1.8%) than in the rifampin group (0.08%, P<.001).
  
  
  CONCLUSIONS
  Compared with a 9-month isoniazid regimen, a 4-month rifampin regimen was associated with a higher percentage of patients completing treatment and a lower percentage of patients with clinically recognized adverse reactions. Additional studies are warranted to determine efficacy and effectiveness of rifampin therapy for LTBI.
authors.affiliation: Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
authors.forename: Kathleen R
authors.initials: KR
authors.lastname: Page
authors.forename: Frangiscos
authors.initials: F
authors.lastname: Sifakis
authors.forename: Ruben
authors.initials: R
authors.lastname: Montes de Oca
authors.forename: Wendy A
authors.initials: WA
authors.lastname: Cronin
authors.forename: Meg C
authors.initials: MC
authors.lastname: Doherty
authors.forename: Lynn
authors.initials: L
authors.lastname: Federline
authors.forename: Sarah
authors.initials: S
authors.lastname: Bur
authors.forename: Thomas
authors.initials: T
authors.lastname: Walsh
authors.forename: Walter
authors.initials: W
authors.lastname: Karney
authors.forename: James
authors.initials: J
authors.lastname: Milman
authors.forename: Nancy
authors.initials: N
authors.lastname: Baruch
authors.forename: Akintoye
authors.initials: A
authors.lastname: Adelakun
authors.forename: Susan E
authors.initials: SE
authors.lastname: Dorman
mesh_terms: D000293:Adolescent; D000328:Adult; D000904:Antibiotics, Antitubercular / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D010349:Patient Compliance / Q000706:statistics & numerical data*; D012189:Retrospective Studies; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012959:Socioeconomic Factors; D016896:Treatment Outcome; D014376:Tuberculosis / Q000188:drug therapy*
chemical_list: D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin